compound indication pre-clinical phase 1 phase 2 phase 3
op-352 Stress Urinary Incontinence
Fecal Incontinence
compound indication phase
op-352 Stress Urinary Incontinence Phase 1
Fecal Incontinence Phase 1

Stress Urinary Incontinence (SUI)

Urinary incontinence is the involuntary leakage of urine which can have a debilitating impact on physical, emotional, and social quality of life.  There are different types of incontinence, distinguished by their associated symptoms and underlying mechanisms.  Stress urinary incontinence (SUI) is incontinence on effort or...View More

Stress Urinary Incontinence (SUI)

Urinary incontinence is the involuntary leakage of urine which can have a debilitating impact on physical, emotional, and social quality of life.  There are different types of incontinence, distinguished by their associated symptoms and underlying mechanisms.  Stress urinary incontinence (SUI) is incontinence on effort or exertion, or on sneezing or coughing. Normally, the urethral sphincter withstands the increased bladder pressure that occurs when it is compressed as a result of increased intra-abdominal pressure caused by these activities.  In SUI, however, there is impaired sphincter function, which results in leakage. This predominantly affects women, in many of whom it can be attributed to damage that occurs during childbirth.  It is estimated that 1 in 3 women will suffer from SUI during their lifetime. Principal treatment options for SUI currently include pelvic floor muscle training (PFMT) and surgery.  PFMT involves multiple training sessions each day over a period of several months leading to low compliance and limited overall effectiveness.  Surgery, while effective, is typically reserved for more severe cases resulting in relatively few patients benefiting from this treatment modality.  An effective pharmacologic therapy could revolutionize care for women suffering from SUI.

Fecal Incontinence (FI)

Fecal incontinence is the complaint of involuntary loss of bowel contents. This can range from occasional leakage of a small quantity of stool (feces) while passing gas to a complete loss of bowel control. Nearly 10% of people are affected by fecal incontinence, but this prevalence increases...View More

Fecal Incontinence (FI)

Fecal incontinence is the complaint of involuntary loss of bowel contents. This can range from occasional leakage of a small quantity of stool (feces) while passing gas to a complete loss of bowel control. Nearly 10% of people are affected by fecal incontinence, but this prevalence increases considerably with age, with approximately 20% of people over the age of 65 being affected and 50% of those in long-term care facilities. Those who suffer from FI often experience considerable embarrassment, which in turn can lead to social insecurity, isolation, and a diminished quality of life. The ability to hold stool (called continence) requires the rectum, anus and nervous system to be working normally. This allows stool to be stored in the rectum, and for defecation to occur at a time and in a place that is socially convenient.  Two groups of muscles, the external and internal anal sphincter, in the wall of the anus and rectum are responsible for holding the stool and avoiding leakage. In addition, the rectum needs to sense the presence of stool and remain in a relaxed state until voluntary defecation occurs.  Most treatments for FI are targeted at improving the strength of the anal sphincter or enhancing voluntary control over rectal contraction via non-pharmacologic methods such as physiotherapy and behavioral modification and treating associated diarrhea or constipation.  A novel pharmacologic approach would offer an important new treatment option for the many patients for whom current treatments are ineffective or too invasive.